The role of combination chemo-immunotherapy in advanced non-small cell lung cancer

References

• GA, Temin S Azzoli CG, et al. Systemic therapy for stage iv non–small-cell lung cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol. 2015;33(30):3488–3515. doi:10.1200/JCO.2015.62.1342
   PubMed Web of Science ®Google Scholar
• Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non–small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35(30):3484–3515. .
   PubMed Web of Science ®Google Scholar
• Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v1–v27.
   PubMed Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(suppl 4):iv192–iv237. .
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer, version 3.2019. National comprehensive cancer network website [Internet]. [cited May 2019]. Available from: nccn.org/professionals/physician_gls/pdf/nscl.pdf
   Google Scholar
• Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (Keynote-042): a randomized open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–1830.
   PubMed Web of Science ®Google Scholar
• fda.gov [Internet]. Silver Spring (MD): FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS ≥1%). [cited May 2019]. Available from: https://www.fda.gov/drugs/fda-expands-pembrolizumab-indication-first-line-treatment-nsclc-tps-1
   Google Scholar
• Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300.
   PubMed Web of Science ®Google Scholar
• Xia W, Yu X, Mao Q, et al. Improvement of survival for non-small cell lung cancer over time. Onco Targets Ther. 2017;10:4295–4303.
   PubMedGoogle Scholar
• Barreto JN, McCullough KB, Ice LL, et al. Antineoplastic agents and the associated myelosuppressive effects: a review. J Pharm Pract. 2014;27(5):440–446.
   PubMedGoogle Scholar
• Chaudhary B, Elkord E. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines (Basel). 2016;4(3):pii: E28.
   PubMed Web of Science ®Google Scholar
• Wang Z, Till B, Gao Q. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology. 2017;6(7):e1331807.
   PubMed Web of Science ®Google Scholar
• Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436–443.
   PubMed Web of Science ®Google Scholar
• Blumenschein G, Chandler J, Garon EB, et al. CheckMate 370: A master protocol of phase 1/2 studies of nivolumab as maintenance or first-line ± standard-of-care therapies in advanced NSCLC. J Thorac Oncol. 2016;11(11, Supplement):S307.
   Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum‐based doublet chemotherapy for first-line treatment of advanced non–small-cell lung cancer. J Clin Oncol. 2016;34(25):2969–2979.
   PubMed Web of Science ®Google Scholar
• Juergens R, Hellmann M, Brahmer J, et al. First-line nivolumab plus platinum-based doublet chemotherapy for advanced NSCLC: checkMate 012 3-year update. J Thorac Oncol. 2017;12(11, Supplement 2):S1792–S1793.
   Web of Science ®Google Scholar
• Borghaei H, Hellmann MD, Paz-Ares LG, et al. Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: results from CheckMate 227. J Clin Oncol. 2018;36(15_suppl):9001.
   Web of Science ®Google Scholar
• Hellmann MD, Ciuleanu T-E, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. NEJM. 2018;378(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): national library of medicine (U.S.) A study of nivolumab in combination with ipilimumab (Part 1); and nivolumab plus ipilimumab in combination with chemotherapy (Part 2) as first line therapy in stage IV non-small cell lung cancer (NSCLC); Identifier: NCT02659059. [cited Mar 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT02659059
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): national library of medicine (U.S.) A Phase 3, randomized study of nivolumab plus ipilimumab in combination with chemotherapy vs chemotherapy alone as first line therapy in stage IV non-small cell lung cancer; Identifier: NCT03215706. [cited Mar 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT03215706
   Google Scholar
• Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–1508.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Langer CJ, Gadgeel S, et al. 24-month overall survival from KEYNOTE-021 Cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2019 Jan;14(1):124–129.
   PubMed Web of Science ®Google Scholar
• Gentzler RD, Langer CJ, Borghaei H, et al. 24-month overall survival from KEYNOTE-021 cohort G: pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC. J Clin Oncol. 2018;36(15_suppl):9026.
   Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic Non–small-cell lung cancer. N Engl J Med. 2018;378:2078–2092. .
   PubMed Web of Science ®Google Scholar
• fda.gov [Internet]. Silver spring (MD): U.S. Food and Drug Administration FDA grants regular approval for pembrolizumab in combination with chemotherapy for first-line treatment of metastatic nonsquamous NSCLC. [cited Mar 2019]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617471.htm
   Google Scholar
• Merck & Co., Inc. [internet] European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous NSCLC, with No EGFR or ALK genomic tumor aberrations, [cited 2019 Mar]. Available from: https://investors.merck.com/news/press-release-details/2018/European-Commission-Approves-Mercks-KEYTRUDA-pembrolizumab-in-Combination-with-Pemetrexed-and-Platinum-Chemotherapy-for-the-First-Line-Treatment-of-Patients-with-Metastatic-Nonsquamous-NSCLC-with-No-EGFR-or-ALK-Genomic-Tumor-Aberrations/default.aspx
   Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med. 2018;379:2040–2051. .
   PubMed Web of Science ®Google Scholar
• fda.gov [Internet]. Silver Spring (MD): U.S. Food and Drug Administration FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC. [cited 2019 Mar]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm624659.htm
   Google Scholar
• Merck & Co., Inc. [internet] European medicines agency adopts positive opinion for Merck’s KEYTRUDA® (pembrolizumab) in combination with chemotherapy for first-line treatment of adults with metastatic squamous Non-Small Cell Lung Cancer (NSCLC). [cited 2019 Mar]. Available from: https://investors.merck.com/news/press-release-details/2019/European-Medicines-Agency-Adopts-Positive-Opinion-for-Mercks-KEYTRUDA-pembrolizumab-in-Combination-with-Chemotherapy-for-First-Line-Treatment-of-Adults-with-Metastatic-Squamous-Non-Small-Cell-Lung-Cancer-NSCLC/default.aspx
   Google Scholar
• M, Papadimitrakopoulou VACappuzzo F, et al. Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy. Oncol. 2016;27(Issuesuppl_6):1294TiP2016.
   Google Scholar
• roche.com [Internet] Roche media release: phase III IMpower130 study showed Roche’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone. [cited 2019 Mar]. Available from: https://www.roche.com/media/releases/med-cor-2018-05-29.htm
   Google Scholar
• West HJ, Nishio M, Dols MC, et al. IMpower132: A phase III clinical program—1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC. J Clin Oncol. 2017;35(15_suppl):TPS9101–TPS9101.
   Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–2301. .
   PubMed Web of Science ®Google Scholar
• fda.gov [Internet]. Silver Spring (MD): FDA approves atezolizumab with chemotherapy and bevacizumab for first-line treatment of metastatic non-squamous NSCLC. [cited 2019 Mar]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm627874.htm
   Google Scholar
• F. Hoffmann-La Roche AG. [internet] CHMP recommends EU approval of Roche’s Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer [cited 2019 Mar]. Available from: https://www.roche.com/media/releases/med-cor-2019-02-01b.htm
   Google Scholar
• Jotte RM, Cappuzzo F, Vynnychenko I, et al. IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J Clin Oncol. 2018;36(18_suppl):LBA9000–LBA9000.
   Web of Science ®Google Scholar
• Remon J, Mezquita L, Corral J, et al. Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. J Thorac Dis. 2018;10(Suppl 13):S1516–S1533.
   PubMedGoogle Scholar
• Nishijima TF, Shachar SS, Nyrop KA, et al. Safety and Tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist. 2017;22(4):470–479.
   PubMed Web of Science ®Google Scholar
• Rocco D, Della Gravara L, Avellino A, et al. Immunotherapy as a targeted therapy in non-small cell lung cancer. Transl Cancer Res. 8(Suppl 1):S70–S75. .
   Web of Science ®Google Scholar
• Kanai O, Kim YH, Demura Y, et al. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thorac Cancer. 2018;9(7):847–855.
   PubMed Web of Science ®Google Scholar
• Kang DH, Chung C, Kim JO, et al. Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors. Thorac Cancer. 2018;9(11):1500–1508.
   PubMed Web of Science ®Google Scholar
• Wang PF, Chen Y, Song SY, et al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017;8:730.
   PubMed Web of Science ®Google Scholar
• De Velasco G, Je Y, Bossé D, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients cancer immunol res. Cancer Immunol Res. 2017;5(4):312–318.
   PubMed Web of Science ®Google Scholar
• Hu YB, Zhang Q, Li HJ, et al. Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2017;6(Suppl 1):S8–S20.
   PubMed Web of Science ®Google Scholar
• Trinh S, Le A, Gowani S, et al. Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines. Asia Pac J Oncol Nurs. 2019;6:154–160.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–1768.
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2018;26(21):3543–3551.
   Google Scholar
• Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374(9699):1432–1440.
   PubMed Web of Science ®Google Scholar